Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Glioblastoma 4Glioma 3Breast Neoplasms 3Brain Neoplasms 3Cholangiocarcinoma 2Central Nervous System Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma 1Colonic Neoplasms 1Chondrosarcoma 1

Interventions

Filgrastim 3enasidenib 2Ifosfamide 2Gemcitabine 2Docetaxel 2Carboplatin 2ivosidenib 1etoposide phosphate 1durvalumab 1Topotecan 1Thiotepa 1Thalidomide 1Radiosurgery 1Quality of Life 1Peripheral Blood Stem Cell Transplantation 1Pentetic Acid 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Minocycline 1Metformin 1Immunotherapy 1Immunologic Techniques 1Heparin 1Gelclair 1Fentanyl 1Etoposide 1Drug Therapy 1Cyproheptadine 1Cyclophosphamide 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × durvalumab × CNS × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡